Eli Lilly launched Mounjaro in NZ February 2026 via Medsafe approval; private telehealth (Well Revolution + Pocket Lab) stocking from launch week. Wegovy still pending Medsafe filing. Foundayo (orforglipron) MHRA / EMA / Medsafe trajectory all 12-18 months behind FDA. What NZ readers can do today.
MOH Circular 87/2024 hit its one-year anniversary in March; the in-person-consultation rule is now observable, not theoretical. Foundayo (orforglipron) HSA pathway tracking 12-18 months behind FDA. Oral Wegovy 25mg HSA filing the more imminent question. What changed for SG readers since the April buyer's guide.
What changed for UK GLP-1 access since the April 2026 buyer's guide. NHS QOF tirzepatide indicators went live April 1; Cohort 2 (BMI 35-39.9) starts June; oral Wegovy 25mg shipped at private pharmacies in January; Foundayo (orforglipron) MHRA pathway tracked. Private market still dominant. What to do today.
What actually shifted in the last 60 days: Foundayo (orforglipron) approved early under the National Priority Voucher, oral Wegovy 25mg shipping, FDA proposes excluding tirzepatide from 503B bulks, RFK pulled 14 peptides off Category 2, survodutide phase 3 obesity readout. Routing impact for each.
Metabolic.Health, Endocare, Zone.Health, DarDoc, Valeo, Limitless Human, Hortman, Novomed. AED pricing, DHA / DOH posture, Foundayo arrival, and how to pick the right Emirates GLP-1 route.